Skip to main content
OpenTrials
Completed

NCT Number: NCT00678899

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System

The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sensorineural Hearing Loss Ear Diseases Hearing Disorders Hearing Loss Hearing Loss, Sensorineural Nervous System Diseases Neurologic Manifestations Otorhinolaryngologic Diseases Pathological Conditions, Signs and Symptoms Sensation Disorders Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Medical Center

New York, 10016, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eighteen years of age or older at the time of implantation.
  • Severe to profound (a threshold average of 2000, 3000, & 4000 Hz > 75dB HL) sensorineural hearing loss for frequencies > 1500 Hz. Low-frequency thresholds up to and including 500 Hz should be no poorer than 60 dB HL.
  • Consonant Nucleus Consonant (CNC) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% <= score <= 60%), in the ear to be implanted.
  • CNC word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%.
  • English spoken as a primary language.

Exclusion criteria

  • Duration of severe-to-profound hearing loss greater than 30 years.
  • Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age).
  • Medical or psychological conditions that contraindicate undergoing surgery.
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
  • Conductive overlay of 15 dB or greater at two or more frequencies, in the range 250 to 1000 Hz.
  • Hearing loss of neural or central origin.
  • Diagnosis of Auditory Neuropathy.
  • Active middle-ear infection.
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices.
  • Unwillingness or inability of the candidate to comply with all investigational requirements.
  • Additional handicaps that would prevent or restrict participation in the audiological evaluations.

Treatment and study plan

Nucleus Hybrid L24

Device

Implantation with Nucleus Hybrid L24 cochlear implant

Primary outcomes

  1. Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)

    Time frame: 6 Months Postactivation

    The co-primary study endpoints will be statistically significant differences between the mean, preoperative monosyllabic CNC word score (unilateral acoustic, ear to be implanted) and the postoperative monosyllabic CNC word scores (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects.

    The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and scored as a total number of words correct, which will be expressed as a percentage correct for this study.

  2. AzBio Sentence Score in Noise - Treated Ear (Co-Primary)

    Time frame: 6 Months Postactivation

    The co-primary study endpoints will be statistically significant differences between the mean, preoperative AzBio Sentences score in noise (unilateral acoustic, ear to be implanted) and postoperative AzBio Sentences score in noise (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects.

    The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts towards the overall score.

Secondary outcomes

  1. Consonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear

    Time frame: 6 Months Postactivation

    Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows:

    The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field. The percentage of subjects that scored equal to or better than they did in the pre-operative unilateral acoustic-only condition will be reported.

  2. AzBio Sentence Score-Treated Ear

    Time frame: 6 Months Postactivation

    Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows:

    The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in'unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score. The percentage of subjects that scored equal to or better than they did in the pre-operative acoustic only condition will be reported.

Sponsors and collaborators

Lead sponsor

Cochlear

Industry

Registry information

Official study title

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant

Important dates

Study start
2008
Primary completion
2012
Study completion
2014
First posted
May 16, 2008
Registry last updated
Jul 15, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.